Fate Therapeutics

company

About

Fate Therapeutics is a stem cell and developmental biology research company using biological mechanisms to develop stem cell therapeutics.

  • 101 - 250

Details

Last Funding Type
Series A
Last Funding Money Raised
$12M
Industries
Biotechnology,Health Care,Therapeutics
Founded date
Jan 1, 2007
Number Of Employee
101 - 250
Operating Status
Active

Fate Therapeutics is using the fundamental biological mechanisms that guide cell fate to develop stem cell therapeutics.

The company has brought together the foremost scientists from the nation's research hotbeds (Boston, San Francisco, San Diego, and Seattle) who have demonstrated the potential to create and modulate stem cells to restore health.

The backstory is that while others were working towards therapies based on transplanting stem cell-derived cells into patients, Randall Moon (HHMI and the University of Washington) and Alex Rives (Arch Venture Capitol) envisioned a different approach to develop regenerative therapies. The concept, based on data from hematopoietic progenitor cells, was that one could modulate the properties of stem cells in vivo using small molecules or biologics. They presented this idea to Arch Venture Capitol in Seattle, which launched the company, soon to be joined by other investors.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$77.98M
Fate Therapeutics has raised a total of $77.98M in funding over 2 rounds. Their latest funding was raised on May 5, 2011 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
May 5, 2011 Series B $35.98M 1 Detail
Nov 16, 2009 Series B $30M 1 Detail
Nov 29, 2007 Series A $12M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Fate Therapeutics is funded by 1 investors. ARCH Venture Partners are the most recent investors.
Investor Name Lead Investor Funding Round
ARCH Venture Partners Series B